38 min listen
Inhalable mRNA with Ethris' Carsten Rudolph, Ph.D.
Inhalable mRNA with Ethris' Carsten Rudolph, Ph.D.
ratings:
Length:
47 minutes
Released:
Feb 5, 2024
Format:
Podcast episode
Description
Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma. Having acknowledged that, no first iteration of a new technology is ever the best iteration of that technology. On this week's episode of the Business of Biotech, we welcome Carsten Rudolph, Ph.D., co-founder and CEO of a company that recognizes this room for improvement. Ethris is developing mRNA-based candidates for the treatment of respiratory viral infections and rare pulmonary diseases, in addition to mucosal, multivalent, and mutation-agnostic prophylactic vaccines. Dr. Rudolph explains the concept, the business case, and how he's navigating Ethris toward a better treatment and vaccine paradigm in the wake of the pandemic. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
Released:
Feb 5, 2024
Format:
Podcast episode
Titles in the series (100)
010: Gap Analysis With Dr. Pablo Valenzuela & Cristián Hernández-Cuevas by Business Of Biotech